Sandra Gardiner
Acting Chief Financial Officer
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2026-05-15
-
Start not stated–2026-05-15
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Nektar Therapeutics (NKTR) | Interim Chief Financial Officer | — | $460,850 |
| 2023 | Nektar Therapeutics (NKTR) | Interim Chief Financial Officer | — | $376,300 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.